Company profile
BlossomHill Therapeutics, Inc.
NASDAQ:BLSMBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06501196 | phase1 | recruiting | 2024-06-19 | 2026-06-01 | BlossomHill Therapeutics | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome |
| NCT06706076 | phase1_2 | recruiting | 2025-01-09 | 2029-01-31 | BlossomHill Therapeutics | A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations |
FDA applications (0)
No records yet.